Loading...

Robert Henry

TitleSenate Emeritus
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #9111G
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Epicatechin and derivatives to preserve muscle structure function in diabetes
    NIH/NIDDK R01DK098717Mar 10, 2014 - Dec 31, 2017
    Role: Principal Investigator
    Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
    NIH/NCCIH R01AT008310Sep 1, 2013 - Aug 31, 2014
    Role: Principal Investigator
    Function of the Myo-adipo Axis in Human Obesity and Type 2 Diabetes
    VA I01CX000635Apr 1, 2012 - Mar 31, 2016
    Role: Principal Investigator
    Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes
    NIH/NIDDK R01DK058291Sep 1, 2001 - Jul 31, 2006
    Role: Principal Investigator
    COMPARATIVE STUDIES OF INTRACELLULAR GLUCOSE METABOLISM
    NIH/NIDDK R29DK038949Sep 30, 1988 - Aug 31, 1994
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry R, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care. 2018 Jun 14. PMID: 29903845.
      View in: PubMed
    2. Yamamoto CM, Murakami T, Oakes ML, Mitsuhashi M, Kelly C, Henry R, Sharma K. Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus. Am J Nephrol. 2018; 47(5):283-291. PMID: 29779026.
      View in: PubMed
    3. Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry R, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018 Jun; 20(6):1479-1489. PMID: 29436756.
      View in: PubMed
    4. Henry R, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes Obes Metab. 2018 Mar 01. PMID: 29493859.
      View in: PubMed
    5. Moreno-Ulloa A, Nájera-García N, Hernández M, Ramírez-Sánchez I, Taub PR, Su Y, Beltrán-Partida E, Ceballos G, Dugar S, Schreiner G, Best BM, Ciaraldi TP, Henry R, Villarreal F. A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints. Food Funct. 2018 Jan 24; 9(1):307-319. PMID: 29171848.
      View in: PubMed
    6. Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, Cava E, Thai D, Shi J, Yan H, Bautista E, McMillan J, Unger R, Henry R, Klein S. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May; 20(5):1302-1305. PMID: 29283470.
      View in: PubMed
    7. Henry R, Rosenstock J, Denham DS, Prabhakar P, Kjems L, Baron MA. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diabetes Care. 2018 Mar; 41(3):613-619. PMID: 29301824.
      View in: PubMed
    8. Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry R. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017 Dec; 19(12):1781-1792. PMID: 28905478.
      View in: PubMed
    9. Seo JA, Kang MC, Ciaraldi TP, Kim SS, Park KS, Choe C, Hwang WM, Lim DM, Farr O, Mantzoros C, Henry R, Kim YB. Circulating ApoJ is closely associated with insulin resistance in human subjects. Metabolism. 2018 Jan; 78:155-166. PMID: 28986164.
      View in: PubMed
    10. Garg SK, Henry R, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 12 14; 377(24):2337-2348. PMID: 28899222.
      View in: PubMed
    11. Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry R. Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia. 2017 Oct; 60(10):2052-2065. PMID: 28770317.
      View in: PubMed
    12. Sun XJ, Kim SP, Zhang D, Sun H, Cao Q, Lu X, Ying Z, Li L, Henry R, Ciaraldi TP, Taylor SI, Quon MJ. Deletion of interleukin 1 receptor-associated kinase 1 (Irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle. J Biol Chem. 2017 07 21; 292(29):12339-12350. PMID: 28572512.
      View in: PubMed
    13. Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry R, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017 May 25; 16(1):70. PMID: 28545518.
      View in: PubMed
    14. Henry R, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting ß-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab. 2017 06; 19(6):814-821. PMID: 28098426.
      View in: PubMed
    15. Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry R, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr). 2016 Dec; 38(5-6):485-493. PMID: 27585671.
      View in: PubMed
    16. Henry R, Klein EJ, Han J, Iqbal N. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. Diabetes Technol Ther. 2016 11; 18(11):677-686. PMID: 27525540.
      View in: PubMed
    17. Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry R, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016 Oct 14; 37(39):2981-2989. PMID: 27460890.
      View in: PubMed
    18. Ciaraldi TP, Ryan AJ, Mudaliar SR, Henry R. Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes. PLoS One. 2016; 11(7):e0158209. PMID: 27453994; PMCID: PMC4959771.
    19. Polonsky WH, Henry R. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10:1299-307. PMID: 27524885; PMCID: PMC4966497.
    20. Mudaliar S, Alloju S, Henry R. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 07; 39(7):1115-22. PMID: 27289124.
      View in: PubMed
    21. Handelsman Y, Henry R, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun; 22(6):753-62. PMID: 27082665.
      View in: PubMed
    22. Peters AL, Henry R, Thakkar P, Tong C, Alba M. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care. 2016 04; 39(4):532-8. PMID: 26989182.
      View in: PubMed
    23. Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. J Clin Endocrinol Metab. 2016 05; 101(5):2056-62. PMID: 26982008.
      View in: PubMed
    24. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry R, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113. PMID: 26731084.
      View in: PubMed
    25. Mudaliar S, Polidori D, Zambrowicz B, Henry R. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care. 2015 Dec; 38(12):2344-53. PMID: 26604280.
      View in: PubMed
    26. Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry R, Hirsch JD. Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients. Ann Pharmacother. 2016 Jan; 50(1):8-16. PMID: 26546580.
      View in: PubMed
    27. Henry R, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care. 2015 Dec; 38(12):2258-65. PMID: 26486192.
      View in: PubMed
    28. Ma GS, Lopez-Sanchez I, Aznar N, Kalogriopoulos N, Pedram S, Midde K, Ciaraldi TP, Henry R, Ghosh P. Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity. Mol Biol Cell. 2015 Nov 15; 26(23):4209-23. PMID: 26378251; PMCID: PMC4642855.
    29. DeFronzo RA, Ferrannini E, Groop L, Henry R, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015 07 23; 1:15019. PMID: 27189025.
      View in: PubMed
    30. Eckel RH, Henry R, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care. 2015 Jul; 38(7):1189-96. PMID: 26049552; PMCID: PMC4477340.
    31. Amir Levy Y, Ciaraldi TP, Mudaliar SR, Phillips SA, Henry R. Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor. Am J Physiol Endocrinol Metab. 2015 Jul 01; 309(1):E22-34. PMID: 25944879.
      View in: PubMed
    32. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry R, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract. 2015 Apr; 21(4):413-37. PMID: 27408942.
      View in: PubMed
    33. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry R, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr; 21 Suppl 1:1-87. PMID: 25869408; PMCID: PMC4959114.
    34. Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab. 2015 May; 100(5):1855-62. PMID: 25603459; PMCID: PMC4422894.
    35. Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry R, Ciaraldi TP, Murphy AN, Metallo CM. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell. 2014 Nov 06; 56(3):425-35. PMID: 25458843; PMCID: PMC4267523.
    36. Henry R, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015 Mar; 38(3):412-9. PMID: 25271207.
      View in: PubMed
    37. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Hill Golden S, Rich S, Reynolds L. Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care. 2014 Jul; 37(7):1782-5. PMID: 25093231.
      View in: PubMed
    38. Henry R, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014 Sep; 37(9):2609-15. PMID: 24947791.
      View in: PubMed
    39. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry R, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16; 311(15):1515-25. PMID: 24682069.
      View in: PubMed
    40. DePaoli AM, Higgins LS, Henry R, Mantzoros C, Dunn FL. Can a selective PPAR? modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014 Jul; 37(7):1918-23. PMID: 24722496.
      View in: PubMed
    41. Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. Diabetes Care. 2014 Jun; 37(6):1706-11. PMID: 24705615; PMCID: PMC4179517.
    42. Fonseca VA, Devries JH, Henry R, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014 May-Jun; 28(3):399-405. PMID: 24561125; PMCID: PMC4231710.
    43. Henry R, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014 May-Jun; 28(3):393-8. PMID: 24631129.
      View in: PubMed
    44. Mudaliar S, Henry R, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014 Mar; 16(3):137-44. PMID: 24237386.
      View in: PubMed
    45. Gutierrez-Salmean G, Ciaraldi TP, Nogueira L, Barboza J, Taub PR, Hogan MC, Henry R, Meaney E, Villarreal F, Ceballos G, Ramirez-Sanchez I. Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem. 2014 Jan; 25(1):91-4. PMID: 24314870; PMCID: PMC3857584.
    46. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Gonzalez-Basurto S, Coral-Vazquez R, Perkins G, Hogan M, Maisel AS, Henry R, Ceballos G, Villarreal F. Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. Clin Sci (Lond). 2013 Oct; 125(8):383-9. PMID: 23642227.
      View in: PubMed
    47. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013 Nov; 36(11):3607-12. PMID: 24062330; PMCID: PMC3816921.
    48. Ciaraldi TP, Aroda V, Mudaliar SR, Henry R. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism. 2013 Nov; 62(11):1587-96. PMID: 23958241.
      View in: PubMed
    49. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry R, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor a/? agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013 Sep; 166(3):429-34. PMID: 24016490.
      View in: PubMed
    50. Ramirez-Sanchez I, Taub PR, Ciaraldi TP, Nogueira L, Coe T, Perkins G, Hogan M, Maisel AS, Henry R, Ceballos G, Villarreal F. (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. Int J Cardiol. 2013 Oct 09; 168(4):3982-3990. PMID: 23870648; PMCID: PMC3805662.
    51. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013 Nov; 62(11):3920-6. PMID: 23863810; PMCID: PMC3806596.
    52. Henry R, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug; 98(8):3446-53. PMID: 23733372.
      View in: PubMed
    53. Mudaliar S, Henry R, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013 Sep; 145(3):574-82.e1. PMID: 23727264.
      View in: PubMed
    54. Henry R, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18. PMID: 23726071; PMCID: PMC4139280.
    55. Cefalu WT, Rosenstock J, Henry R, Riddle M. Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance. Diabetes Care. 2013 Jul; 36(7):1804-6. PMID: 23695816; PMCID: PMC3687287.
    56. Meyer LK, Ciaraldi TP, Henry R, Wittgrove AC, Phillips SA. Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte. 2013 Oct 01; 2(4):217-26. PMID: 24052897; PMCID: PMC3774697.
    57. Henry R, Rosenstock J, Logan DK, Alessi TR, Luskey K, Baron MA. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care. 2013 Sep; 36(9):2559-65. PMID: 23645886; PMCID: PMC3747935.
    58. Henry R, Logan D, Alessi T, Baron MA. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Clin Ther. 2013 May; 35(5):634-645.e1. PMID: 23578605.
      View in: PubMed
    59. Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Loviscach M, Wall EA, Yadava N, Heuck AP, Ferrick DA, Henry R, McDonald WG, Colca JR, Simon MI, Ciaraldi TP, Murphy AN. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A. 2013 Apr 02; 110(14):5422-7. PMID: 23513224; PMCID: PMC3619368.
    60. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry R. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013 Aug; 36(8):2154-61. PMID: 23412078; PMCID: PMC3714520.
    61. Taub PR, Higginbotham E, Henry R. Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes. Curr Cardiol Rep. 2013 Feb; 15(2):332. PMID: 23314689.
      View in: PubMed
    62. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry R, Lavin N, Tapiador CD, Weyer C. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013 Jan-Feb; 19(1):107-16. PMID: 23435042; PMCID: PMC4108221.
    63. He Z, Zhu HH, Bauler TJ, Wang J, Ciaraldi T, Alderson N, Li S, Raquil MA, Ji K, Wang S, Shao J, Henry R, King PD, Feng GS. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):E79-88. PMID: 23236157; PMCID: PMC3538237.
    64. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry R, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013 Feb; 33(2):393-9. PMID: 23175674; PMCID: PMC3908828.
    65. Mudaliar S, Armstrong DA, Mavian AA, O'Connor-Semmes R, Mydlow PK, Ye J, Hussey EK, Nunez DJ, Henry R, Dobbins RL. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012 Nov; 35(11):2198-200. PMID: 23011728; PMCID: PMC3476920.
    66. Kung J, Henry R. Thiazolidinedione safety. Expert Opin Drug Saf. 2012 Jul; 11(4):565-79. PMID: 22616948.
      View in: PubMed
    67. Aroda VR, Henry R, Han J, Huang W, DeYoung MB, Darsow T, Hoogwerf BJ. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012 Jun; 34(6):1247-1258.e22. PMID: 22608780.
      View in: PubMed
    68. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, Juguilon H, Yin YQ, Phillips CT, Yu RT, Olefsky JM, Henry R, Downes M, Evans RM. A PPAR?-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature. 2012 May 17; 485(7398):391-4. PMID: 22522926; PMCID: PMC3358516.
    69. Henry R, Mudaliar S, Kanitra L, Woloschak M, Balena R. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab. 2012 Jul; 97(7):2370-9. PMID: 22539590.
      View in: PubMed
    70. Perlstein TS, Henry R, Mather KJ, Rickels MR, Abate NI, Grundy SM, Mai Y, Albu JB, Marks JB, Pool JL, Creager MA. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond). 2012 Feb; 122(4):193-202. PMID: 21861845; PMCID: PMC4566948.
    71. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry R, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci. 2012 Feb; 5(1):43-7. PMID: 22376256.
      View in: PubMed
    72. Henry R, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011 Nov-Dec; 17(6):906-13. PMID: 22193143.
      View in: PubMed
    73. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry R, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24; 364(12):1104-15. PMID: 21428766.
      View in: PubMed
    74. Jin W, Goldfine AB, Boes T, Henry R, Ciaraldi TP, Kim EY, Emecan M, Fitzpatrick C, Sen A, Shah A, Mun E, Vokes V, Schroeder J, Tatro E, Jimenez-Chillaron J, Patti ME. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar; 121(3):918-29. PMID: 21393865; PMCID: PMC3049368.
    75. Chun KH, Choi KD, Lee DH, Jung Y, Henry R, Ciaraldi TP, Kim YB. In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab. 2011 Mar; 300(3):E536-42. PMID: 21189360; PMCID: PMC3064006.
    76. Chao EC, Henry R. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 Jul; 9(7):551-9. PMID: 20508640.
      View in: PubMed
    77. Bailey DM, McEneny J, Mathieu-Costello O, Henry R, James PE, McCord JM, Pietri S, Young IS, Richardson RS. Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985). 2010 Aug; 109(2):449-56. PMID: 20507973; PMCID: PMC2928589.
    78. Mavian AA, Miller S, Henry R. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad Med. 2010 May; 122(3):106-17. PMID: 20463420.
      View in: PubMed
    79. Mudaliar S, Henry R. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med. 2010 Mar; 123(3 Suppl):S19-27. PMID: 20206728.
      View in: PubMed
    80. Kulasa KM, Henry R. Pharmacotherapy of hyperglycemia. Expert Opin Pharmacother. 2009 Oct; 10(15):2415-32. PMID: 19743938.
      View in: PubMed
    81. Defronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry R, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009 Jul 29; 9:17. PMID: 19640291; PMCID: PMC2725044.
    82. Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S, Henry R. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab. 2009 Sep; 297(3):E767-73. PMID: 19622782; PMCID: PMC2739702.
    83. Mudaliar S, Henry R. Incretin therapies: effects beyond glycemic control. Eur J Intern Med. 2009 Jul; 20 Suppl 2:S319-28. PMID: 19580951.
      View in: PubMed
    84. Henry R, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009 Jul 11; 374(9684):126-35. PMID: 19515415.
      View in: PubMed
    85. Mudaliar S, Henry R. Incretin therapies: effects beyond glycemic control. Am J Med. 2009 Jun; 122(6 Suppl):S25-36. PMID: 19464425.
      View in: PubMed
    86. Mafong DD, Henry R. The role of incretins in cardiovascular control. Curr Hypertens Rep. 2009 Feb; 11(1):18-22. PMID: 19146796.
      View in: PubMed
    87. Phillips PS, Ciaraldi TP, Kim DL, Verity MA, Wolfson T, Henry R. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine. 2009 Feb; 35(1):38-46. PMID: 19051066.
      View in: PubMed
    88. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry R. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009 Feb; 94(2):469-76. PMID: 18984667; PMCID: PMC2646515.
    89. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry R. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009 Jan; 94(1):157-63. PMID: 18854391; PMCID: PMC2630871.
    90. Savu MK, Phillips SA, Oh DK, Park K, Gerlan C, Ciaraldi TP, Henry R. Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis. 2009 Mar-Apr; 5(2):172-80. PMID: 18996753.
      View in: PubMed
    91. Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry R. Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab. 2008 Oct; 295(4):E842-50. PMID: 18664597; PMCID: PMC2575897.
    92. Henry R. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin. 2008 Aug; 24(8):2189-202. PMID: 18573228.
      View in: PubMed
    93. Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry R. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):343-68. PMID: 18327995.
      View in: PubMed
    94. Mafong DD, Henry R. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008 Feb; 10(1):55-60. PMID: 18366986.
      View in: PubMed
    95. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry R. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008 May; 89(5):1200-8. PMID: 17706206.
      View in: PubMed
    96. Ciaraldi TP, Nikoulina SE, Bandukwala RA, Carter L, Henry R. Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology. 2007 Sep; 148(9):4393-9. PMID: 17569761.
      View in: PubMed
    97. Mudaliar S, Henry R. Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S83-92. PMID: 17563308.
      View in: PubMed
    98. Oh DK, Ciaraldi T, Henry R. Adiponectin in health and disease. Diabetes Obes Metab. 2007 May; 9(3):282-9. PMID: 17391153.
      View in: PubMed
    99. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry R, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007 Mar; 30(3):753-9. PMID: 17327355.
      View in: PubMed
    100. Bailey DM, Lawrenson L, McEneny J, Young IS, James PE, Jackson SK, Henry R, Mathieu-Costello O, McCord JM, Richardson RS. Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res. 2007 Feb; 41(2):182-90. PMID: 17364944.
      View in: PubMed
    101. Lillo JL, Bray G, Woods SC, Henry R, Hadley RD. Cardiometabolic risk modification: current trends and emerging therapies. JAAPA. 2006 Dec; Suppl Cardiometabolic:3-14; quiz 15-6. PMID: 17354517.
      View in: PubMed
    102. Riddle MC, Henry R, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 2006 Nov-Dec; 22(6):483-91. PMID: 16634116.
      View in: PubMed
    103. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry R, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006 Jun 15; 354(24):2552-63. PMID: 16775236.
      View in: PubMed
    104. Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry R. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2006 Nov; 291(5):E891-8. PMID: 16757548.
      View in: PubMed
    105. Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry R. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications. 2006 Jan-Feb; 20(1):14-20. PMID: 16389162.
      View in: PubMed
    106. Shah M, Adams-Huet B, Bantle JP, Henry R, Griver KA, Raatz SK, Brinkley LJ, Reaven GM, Garg A. Effect of a high-carbohydrate versus a high--cis-monounsaturated fat diet on blood pressure in patients with type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2607-12. PMID: 16249527.
      View in: PubMed
    107. Phillips SA, Choe CC, Ciaraldi TP, Greenberg AS, Kong AP, Baxi SC, Christiansen L, Mudaliar SR, Henry R. Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res. 2005 Aug; 13(8):1321-9. PMID: 16129713.
      View in: PubMed
    108. Ciaraldi TP, Phillips SA, Carter L, Aroda V, Mudaliar S, Henry R. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor I. J Clin Endocrinol Metab. 2005 Oct; 90(10):5551-8. PMID: 16030168.
      View in: PubMed
    109. O'Connor DT, Cadman PE, Smiley C, Salem RM, Rao F, Smith J, Funk SD, Mahata SK, Mahata M, Wen G, Taupenot L, Gonzalez-Yanes C, Harper KL, Henry R, Sanchez-Margalet V. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab. 2005 Sep; 90(9):5414-25. PMID: 15956083.
      View in: PubMed
    110. Cha BS, Ciaraldi TP, Park KS, Carter L, Mudaliar SR, Henry R. Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab. 2005 Jul; 289(1):E151-9. PMID: 15727952.
      View in: PubMed
    111. Buse JB, Henry R, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov; 27(11):2628-35. PMID: 15504997.
      View in: PubMed
    112. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, Henry R. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab. 2005 Jan; 90(1):352-8. PMID: 15483099.
      View in: PubMed
    113. Aroda VR, Savu MK, Henry R. Diabetes and obesity: medical diseases, surgical cure? Curr Diab Rep. 2004 Oct; 4(5):317-8. PMID: 15461894.
      View in: PubMed
    114. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry R, Maisel AS. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004 Sep 01; 44(5):1047-52. PMID: 15337217.
      View in: PubMed
    115. Einhorn D, Aroda VR, Henry R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am. 2004 Sep; 33(3):595-616, vii-viii. PMID: 15262299.
      View in: PubMed
    116. Sathyaprakash R, Henry R. Hyperglycemia with antipsychotic treatment. Curr Diab Rep. 2004 Feb; 4(1):41-5. PMID: 14764279.
      View in: PubMed
    117. Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry R, Dananberg J. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003 Dec; 88(12):5875-80. PMID: 14671184.
      View in: PubMed
    118. Grotz VL, Henry R, McGill JB, Prince MJ, Shamoon H, Trout JR, Pi-Sunyer FX. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc. 2003 Dec; 103(12):1607-12. PMID: 14647086.
      View in: PubMed
    119. Henry R, Mudaliar S, Chu N, Kim D, Armstrong D, Davis TT, An B, Reinhardt RR. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol. 2003 Nov; 43(11):1228-34. PMID: 14551177.
      View in: PubMed
    120. Mudaliar S, Chang AR, Henry R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003 Sep-Oct; 9(5):406-16. PMID: 14583425.
      View in: PubMed
    121. Chandran M, Phillips SA, Ciaraldi T, Henry R. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003 Aug; 26(8):2442-50. PMID: 12882876.
      View in: PubMed
    122. Kim YB, Kotani K, Ciaraldi TP, Henry R, Kahn BB. Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes. 2003 Aug; 52(8):1935-42. PMID: 12882908.
      View in: PubMed
    123. Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry R. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism. 2003 May; 52(5):540-6. PMID: 12759881.
      View in: PubMed
    124. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry R. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2003 Aug; 285(2):E354-62. PMID: 12700163.
      View in: PubMed
    125. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003 Mar; 52(3):667-74. PMID: 12606507.
      View in: PubMed
    126. Henry R, Mudaliar SR, Howland WC, Chu N, Kim D, An B, Reinhardt RR. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care. 2003 Mar; 26(3):764-9. PMID: 12610035.
      View in: PubMed
    127. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry R. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 Jan; 26(1):1-8. PMID: 12502651.
      View in: PubMed
    128. Henry R. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther. 2003; 25 Suppl B:B47-63. PMID: 14553866.
      View in: PubMed
    129. Sathyaprakash R, Henry R. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep. 2002 Oct; 2(5):416-22. PMID: 12643167.
      View in: PubMed
    130. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi TP, Armstrong D, Kim B, Sha X, Henry R. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care. 2002 Sep; 25(9):1597-602. PMID: 12196433.
      View in: PubMed
    131. Ciaraldi TP, Carter L, Rehman N, Mohideen P, Mudaliar S, Henry R. Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. Metabolism. 2002 Sep; 51(9):1171-9. PMID: 12200763.
      View in: PubMed
    132. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry R. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes. 2002 Jul; 51(7):2190-8. PMID: 12086949.
      View in: PubMed
    133. Ciaraldi TP, Cha BS, Park KS, Carter L, Mudaliar SR, Henry R. Free fatty acid metabolism in human skeletal muscle is regulated by PPARgamma and RXR agonists. Ann N Y Acad Sci. 2002 Jun; 967:66-70. PMID: 12079836.
      View in: PubMed
    134. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry R, Reaven PD. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002 Mar; 25(3):542-9. PMID: 11874944.
      View in: PubMed
    135. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry R, Kahn BB. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002 Feb; 51(2):443-8. PMID: 11812753.
      View in: PubMed
    136. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry R. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes. 2002 Jan; 51(1):30-6. PMID: 11756319.
      View in: PubMed
    Robert's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _